Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Lymphoma, Non-Hodgkin 37Lymphoma 37Lymphoma, Follicular 33Lymphoma, Large B-Cell, Diffuse 30Lymphoma, Mantle-Cell 22Lymphoma, B-Cell, Marginal Zone 13Leukemia, Lymphocytic, Chronic, B-Cell 13Waldenstrom Macroglobulinemia 9Lymphoma, Large-Cell, Immunoblastic 9Burkitt Lymphoma 9Lymphoma, B-Cell 6Lymphoma, Large-Cell, Anaplastic 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Multiple Myeloma 2Leukemia 2Recurrence 1Orbital lymphoma 1Oncology Patients Receiving Chemotherapy 1Neoplasms, Plasma Cell 1Neoplasms by Histologic Type 1Neoplasms 1Lymphoproliferative Disorders 1Lymphoma, AIDS-Related 1Lymphatic Diseases 1Immunoproliferative Disorders 1Immune System Diseases 1Graft vs Host Disease 1Dendritic Cell Sarcoma, Interdigitating 1

Interventions

Dexamethasone 809Bortezomib 449Lenalidomide 430Cyclophosphamide 336Melphalan 251Calcium Dobesilate 237daratumumab 218pomalidomide 202carfilzomib 181fludarabine phosphate 131Thalidomide 121fludarabine 118Peripheral Blood Stem Cell Transplantation 117Filgrastim 111ixazomib 85Mycophenolic Acid 85Granulocyte Colony-Stimulating Factor 84Busulfan 83Whole-Body Irradiation 80Tacrolimus 75dexamethasone acetate 74Cyclosporine 67isatuximab 64Prednisone 64dexamethasone 21-phosphate 63elotuzumab 60auricularum 57belantamab mafodotin 55Antilymphocyte Serum 55Etoposide 52

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Multiple Myeloma × ibritumomab tiuxetan × Clear all
NCT00477815 2018-05-14

Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan, Melphalan, and Autologous Peripheral Stem Cell Transplant in Treating Patients With Previously Treated Multiple Myeloma

Mayo Clinic

Phase 1 Completed
30 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT01207765 2017-03-20

Zevalin for Patients With Incomplete Response to Chemo Prior to Autologous Stem Cell Transplant for Multiple Myeloma

Tufts Medical Center

Phase 2 Terminated
8 enrolled 8 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡